MNOV
MediciNovaยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
MNOV Profile
Medicinova, Inc.
A biopharmaceutical company developing products primarily focused on neurology, respiratory
Biological Technology
09/26/2000
12/07/2006
NASDAQ Stock Exchange
13
12-31
Common stock
4275 Executive Square
Suite 300
La Jolla
California 92037
--
MediciNova, Inc., was originally incorporated in Delaware on September 26, 2000. The company is a biopharmaceutical company focused on developing novel therapies for the treatment of serious diseases with unmet medical needs, with a commercial focus on the US market. The company's current strategy is to concentrate R&D resources to advance the following two core drug candidates: MN-166 (ibudilast): for the treatment of neurological and other related diseases, including progressive multiple sclerosis, amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (such as methamphetamine dependence), And prevention of acute respiratory distress syndrome (ARDS); MN-001 (tipelukast): for the treatment of fibrosis and other metabolic diseases such as non-alcoholic fatty liver disease (NAFLD) and hypertriglyceridemia.
